Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 1/20 | 0.55 |
| ▸ | STAT1 | P42224 | 1/20 | 0.55 |
| ▸ | TOP1 | P11387 | 4/20 | 0.35 |
| ▸ | CYCS | P99999 | 3/20 | 0.34 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.34 |
| ▸ | TERT | O14746 | 3/20 | 0.33 |
| ▸ | PLG | P00747 | 3/20 | 0.33 |
| ▸ | PLAU | P00749 | 3/20 | 0.33 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | ATP4A | P20648 | 1/20 | 0.32 |
| ▸ | ATP4B | P51164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL585094 | 0.93 | STAT3 (0.48) | STAT3STAT1TERTATP4AATP4B | |
| SCHEMBL585272 | 0.88 | STAT3 (0.55) | STAT3STAT1 | |
| SCHEMBL21523873 | 0.86 | STAT3 (0.53) | STAT3STAT1TERTATP4AATP4B | |
| Exeporfinium SCHEMBL585997 | 0.85 | STAT3 (0.52) | STAT3STAT1TOP1CYCSENPP2 | |
| Hydrochloric Acid SCHEMBL29089945 | 0.85 | STAT3 (0.49) | STAT3STAT1ACHEATP4AATP4B | |
| Exeporfinium SCHEMBL584418 | 0.84 | STAT3 (0.51) | STAT3STAT1TOP1CYCSENPP2 | |
| SCHEMBL14038527 | 0.84 | STAT3 (0.51) | STAT3STAT1TERTATP4AATP4B | |
| Exeporfinium SCHEMBL5012396 | 0.84 | STAT3 (0.51) | STAT3STAT1TOP1CYCSENPP2 | |
| SCHEMBL584752 | 0.84 | STAT3 (0.50) | STAT3STAT1TOP1TERT | |
| Hydrochloric Acid SCHEMBL27856204 | 0.84 | STAT3 (0.50) | STAT3STAT1TERTATP4AATP4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080281091-A1 | Process for the Preparation of Porphyrin Derivatives as Antimicrobial Agents by Photodynamic Therapy (Pdt) | BRUNDISH DEREK | 2008-11-13 | — | — | US | claimed |
| EP-1963333-A1 | PROCESS FOR THE PREPARATION OF PORPHYRIN DERIVATIVES AS ANTIMICROBIAL AGENTS BY PHOTODYNAMIC THERAPY (PDT) | Destiny Pharma Limited (GB) | 2008-09-03 | — | — | EP | claimed |
| EP-1578750-B1 | CATIONIC PORPHYRIN DERIVATIVES AS ANTIBACTERIAL AGENTS | DESTINY PHARMA LTD (GB) | 2007-11-21 | — | — | EP | claimed |
| WO-2007074340-A1 | PROCESS FOR THE PREPARATION OF PORPHYRIN DERIVATIVES AS ANTIMICROBIAL AGENTS BY PHOTODYNAMIC THERAPY (PDT) | DESTINY PHARMA LIMITED (GB) | 2007-07-05 | — | — | WO | claimed |
| EP-1768666-B1 | NOVEL USES OF PORPHYRIN COMPOUNDS | DESTINY PHARMA LTD (GB) | 2012-02-15 | — | — | EP | disclosed |
| EP-1768666-B1 | NOVEL USES OF PORPHYRIN COMPOUNDS | DESTINY PHARMA LTD (GB) | 2012-02-15 | — | — | EP | disclosed |
| US-8084602-B2 | Porphyrin derivatives and their use in photodynamic therapy | DESTINY PHARMA LIMITED (CH) | 2011-12-27 | — | — | US | disclosed |
| US-8084602-B2 | Porphyrin derivatives and their use in photodynamic therapy | DESTINY PHARMA LIMITED (CH) | 2011-12-27 | — | — | US | disclosed |
| US-8084602-B2 | Porphyrin derivatives and their use in photodynamic therapy | DESTINY PHARMA LIMITED (CH) | 2011-12-27 | — | — | US | disclosed |
| US-7977474-B2 | Uses of porphyrin compounds | DESTINY PHARMA LTD. (GB) | 2011-07-12 | — | — | US | disclosed |
| US-7977474-B2 | Uses of porphyrin compounds | DESTINY PHARMA LTD. (GB) | 2011-07-12 | — | — | US | disclosed |
| US-7977474-B2 | Uses of porphyrin compounds | DESTINY PHARMA LTD. (GB) | 2011-07-12 | — | — | US | disclosed |
| US-7244841-B2 | Porphyrin derivatives and their use in photodynamic therapy | DESTINY PHARMA LIMITED (GB) | 2007-07-17 | — | — | US | disclosed |
| US-7244841-B2 | Porphyrin derivatives and their use in photodynamic therapy | DESTINY PHARMA LIMITED (GB) | 2007-07-17 | — | — | US | disclosed |
| US-7244841-B2 | Porphyrin derivatives and their use in photodynamic therapy | DESTINY PHARMA LIMITED (GB) | 2007-07-17 | — | — | US | disclosed |
| WO-2007074340-A1 | PROCESS FOR THE PREPARATION OF PORPHYRIN DERIVATIVES AS ANTIMICROBIAL AGENTS BY PHOTODYNAMIC THERAPY (PDT) | DESTINY PHARMA LIMITED (GB) | 2007-07-05 | — | — | WO | disclosed |
| WO-2007074340-A1 | PROCESS FOR THE PREPARATION OF PORPHYRIN DERIVATIVES AS ANTIMICROBIAL AGENTS BY PHOTODYNAMIC THERAPY (PDT) | DESTINY PHARMA LIMITED (GB) | 2007-07-05 | — | — | WO | disclosed |
| EP-1768666-A1 | NOVEL USES OF PORPHYRIN COMPOUNDS | Destiny Pharma Limited (GB) | 2007-04-04 | — | — | EP | disclosed |
| WO-2006000765-A1 | NOVEL USES | DESTINY PHARMA LIMITED (GB) | 2006-01-05 | — | — | WO | disclosed |
| US-20040143001-A1 | Novel compounds and uses thereof | DESTINY PHARMA LIMITED | 2004-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040143001-A1 | Novel compounds and uses thereof | PPOX, CYP19A1, XDH | STAT3 2198/4885STAT1 2107/4885TOP1 593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.